Delirium Market Trends
ID: MRFR/Pharma/4394-CR
128 Pages
January 2024
Delirium Market Research Report Information by Type (Hyperactive, Hypoactive, Mixed), By Diagnosis and treatment (Diagnosis, Treatment) By End-User (Hospitals, Specialty Care, Research Centers), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032
Market Summary
As per Market Research Future Analysis, the Global Delirium Market was valued at USD 0.320 Billion in 2023 and is projected to reach USD 0.512 Billion by 2032, growing at a CAGR of 5.30% from 2024 to 2032. The market growth is driven by an increasing aging population, improved diagnosis, and technological advancements. The aging demographic significantly contributes to the rise in delirium cases, necessitating enhanced diagnostic tools and management strategies. The market is segmented by type, with the Hypoactive segment holding the majority share, and by indication, where the diagnosis segment is expected to grow the fastest. North America leads the market due to its advanced healthcare infrastructure and awareness of delirium's impact on patient care.
Key Market Trends & Highlights
Key trends driving the Delirium Market include demographic shifts and advancements in healthcare technology.
- The aging population is projected to increase from 1 Million in 2020 to 2.1 Million by 2050, boosting demand for delirium management.
- The diagnosis segment is expected to be the fastest-growing, driven by AI and machine learning innovations.
- Hospitals are increasingly focusing on delirium management, leading to a rise in specialized protocols and training programs.
- The North American market accounted for the largest share in 2022, supported by a robust healthcare system.
Market Size & Forecast
| 2023 Market Size | USD 0.320 Billion |
| 2032 Market Size | USD 0.512 Billion |
| CAGR (2024-2032) | 5.30% |
| Largest Regional Market Share in 2022 | North America |
Major Players
Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Novartis AG (Switzerland)
Market Trends
Growing aging population is to boost the market growth
The aging population is a significant driver of the delirium market. As the global population experiences a demographic shift towards older adults, the prevalence of delirium increases. Older individuals are more susceptible to delirium due to factors such as underlying health conditions, cognitive impairments, polypharmacy, and hospitalization. The physiological changes associated with aging, such as alterations in neurotransmitters and decreased cognitive reserve, also contribute to the vulnerability to delirium. The aging population's impact on the delirium market is multifaceted. Firstly, it leads to a greater number of delirium cases, creating a higher demand for diagnostic tools, interventions, and management strategies.
Secondly, the complex medical needs of older patients require tailored approaches to delirium prevention and management. This drives the development of specialized programs, protocols, and guidelines for geriatric delirium care. In October 2022, according to the WHO, the number of people 60 and older will rise from 1 Million in 2020 to 1.4 Million. The number of people 60 and older in the world will double (2.1 Million) by the year 2050. Between 2020 and 2050, there will be 426 million more people who are 80 years of age or older.
Additionally, the aging population influences research and development efforts focused on understanding the underlying mechanisms of delirium and developing age-specific interventions. It also highlights the importance of interdisciplinary collaboration and training to equip healthcare professionals with the knowledge and skills necessary for effective delirium management in older adults. Overall, the growing aging population is a driving force behind the expansion and advancement of the delirium market.
The Global Delirium Market is poised for growth as awareness of the condition increases and healthcare systems adapt to better manage and treat affected populations.
National Institute of Health (NIH)
Delirium Market Market Drivers
Market Growth Projections
The Global Delirium Market Industry is projected to experience substantial growth over the coming years. The market is expected to reach a value of 0.34 USD Billion in 2024, with a significant increase to 0.6 USD Billion by 2035. This growth is indicative of a compound annual growth rate of 5.32% from 2025 to 2035. Such projections highlight the increasing recognition of delirium as a critical health issue and the ongoing efforts to improve its management and treatment across various healthcare settings.
Rising Incidence of Delirium
The Global Delirium Market Industry is experiencing growth due to the increasing incidence of delirium among hospitalized patients. Studies indicate that delirium affects approximately 15 to 30 percent of hospitalized older adults, particularly in intensive care units. This rising prevalence necessitates improved diagnostic and treatment options, thereby driving market expansion. As the global population ages, the number of individuals at risk for delirium is expected to rise, contributing to the market's projected value of 0.34 USD Billion in 2024. This trend underscores the need for healthcare systems to address delirium more effectively.
Advancements in Diagnostic Tools
Technological advancements in diagnostic tools are significantly influencing the Global Delirium Market Industry. Enhanced screening methods and tools, such as the Confusion Assessment Method, are enabling healthcare professionals to identify delirium more accurately and promptly. These innovations not only improve patient outcomes but also facilitate timely interventions, which are crucial in managing delirium. As a result, the market is likely to see an increase in demand for these advanced diagnostic tools, contributing to the projected growth rate of 5.32% CAGR from 2025 to 2035. This growth reflects the ongoing commitment to improving delirium management.
Integration of Telehealth Services
The integration of telehealth services into healthcare systems is emerging as a key driver for the Global Delirium Market Industry. Telehealth platforms facilitate remote monitoring and consultations, allowing healthcare providers to manage delirium cases more effectively, especially in rural or underserved areas. This approach not only enhances access to care but also supports timely interventions, which are critical in managing delirium. As telehealth continues to gain traction, it is likely to contribute to the market's growth, aligning with the projected CAGR of 5.32% from 2025 to 2035, as healthcare systems adapt to evolving patient needs.
Growing Research and Development Initiatives
The Global Delirium Market Industry is benefiting from increased research and development initiatives aimed at understanding and treating delirium. Government and academic institutions are investing in studies that explore the underlying mechanisms of delirium and potential therapeutic interventions. This focus on research is likely to lead to the development of novel treatment options, enhancing the overall management of delirium. As these initiatives progress, they are expected to contribute to the market's growth trajectory, supporting the anticipated increase in market value to 0.6 USD Billion by 2035.
Increased Awareness Among Healthcare Professionals
There is a growing awareness among healthcare professionals regarding the implications of delirium, which is positively impacting the Global Delirium Market Industry. Educational initiatives and training programs are being implemented to enhance understanding of delirium's symptoms and management strategies. This heightened awareness is likely to lead to earlier detection and treatment, thereby improving patient outcomes. As healthcare providers become more knowledgeable, the demand for effective delirium management solutions is expected to rise, further contributing to the market's anticipated growth to 0.6 USD Billion by 2035.
Market Segment Insights
Delirium Type Insights
The Delirium Market segmentation, based on type, includes Hyperactive, Hypoactive, Mixed. The Hypoactive segment is to hold the majority share in 2022 in the Delirium Market revenue. Due to hypoactive characterized by subdued motor activity, poses a unique challenge, necessitating specialized interventions. Pharmaceutical advancements and targeted therapeutic approaches are driving innovation in this market, providing novel treatment options. Healthcare providers are increasingly recognizing the importance of early detection and tailored interventions for hypoactive delirium, contributing to market expansion.
January 7, 2019: Dr. Lata McGinn, Cognitive Behavioural Consultants and Professor at Yeshiva University, announced the launch of the New International Cognitive Behaviour Therapy Organization. The organization is dedicated to the promotion of health and well-being through the scientific development and implementation of evidence-based cognitive behavioural strategies designed to evaluate, prevent, and treat mental conditions and illnesses.
Delirium Indication Insights
The Delirium Market segmentation is based on a Diagnosis and treatment, that includes Diagnosis, and Treatment. The diagnosis segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to integration of artificial intelligence and machine learning algorithms revolutionizing diagnostic approaches, offering more efficient and objective assessments. The growing emphasis on early detection and intervention is driving investments in research and development, fostering a dynamic landscape for diagnostic innovations in the Delirium Market, ultimately improving patient care and outcomes.
Figure 2: DELIRIUM MARKET, BY INDICATION, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review
Delirium End User Insights
The Delirium Market segmentation is based on end-user that includes Hospitals, Speciality Care, and Research Centers. The hospitals segment has dominated the market in 2022 and homecare is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to hospitals increasingly recognizing the significance of delirium in patient care, there is a growing demand for effective solutions and interventions. Delirium management has become a focal point in hospitals, driven by factors such as an aging population and the recognition of delirium's impact on healthcare outcomes.
Hospitals are investing in staff training, awareness programs, and specialized resources to address delirium promptly. The integration of comprehensive delirium protocols within hospital workflows is contributing to improved patient care, creating a positive trajectory for the growth of delirium-related services and products in the global healthcare landscape.
Get more detailed insights about Delirium Market Research Report — Global Forecast till 2032
Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Delirium market accounted for the largest market share in 2022 due to aging population and a rise in chronic illnesses, there is an increased awareness of delirium as a critical aspect of patient care. The region's well-established healthcare infrastructure and advanced medical research contribute to the growth of diagnostic and therapeutic innovations in delirium management. Hospitals and healthcare facilities across North America are integrating specialized protocols, training programs, and advanced technologies to enhance delirium diagnosis and treatment.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: DELIRIUM MARKET BY REGION 2022 & 2032
Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review
Europe Delirium market is expected to account for the second-largest market share due to the favorable health policies and trend towards integrating health services, including counseling. Further, the German Delirium market was attributed to holding the largest market share, and France Delirium market is expected to fastest-growing market in the European region.
The Asia-Pacific healthcare counseling market is expected to grow at the fastest rate from 2024 to 2032. This is due to the rising spending in healthcare, quickly evolving healthcare infrastructure, growing awareness regarding Delirium, and growing population in the region. Moreover, China’s Delirium market is expected to hold the largest market share, and India Delirium market is expected fastest-growing market in the Asia-Pacific region.
The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of Delirium are in the Middle East and Africa. As the region experiences population growth and an increase in age-related conditions, the awareness and recognition of delirium as a significant healthcare concern are on the rise. Healthcare providers in the Middle East and Africa are progressively focusing on implementing effective diagnostic and therapeutic strategies for delirium management.
Key Players and Competitive Insights
The Delirium Market is characterized by the presence of many global, regional, players. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse Type portfolios. Companies such as Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland) dominate the Delirium Market due to Type differentiation, financial stability, strategic services, and diversified regional presence.
The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global Delirium industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs.
Key Companies in the Delirium Market market include
Industry Developments
April 2023, Otsuka Pharmaceutical Co., Ltd (Japan) got approval from US Food and Drug Administration for drug ABILIFY ASIMTUFII (aripiprazole) approval for the treatment of schizophrenia or delirium as well as maintenance monotherapy in people with bipolar I disorder. Moreover, this drug effectively treats delirium.
In April 2023, The US Food and Drug Administration approved Teva Pharmaceutical Industries’ UZEDY (risperidone) an injectable suspension, a long-acting subcutaneous atypical antipsychotic injection, for the treatment of schizophrenia and delirium in adults. Additionally, those who are physically ill could use this medication to decrease the behavioral and cognitive symptoms of delirium.
In September 2022, Ceribell, Inc (US) received US FDA breakthrough device designation from its device Ceribell system for the treatment of delirium indication. This device operates machine learning to examine electroencephalography (EEG) signals to detect delirium.
Future Outlook
Delirium Market Future Outlook
The Global Delirium Market is projected to grow at a 5.32% CAGR from 2024 to 2035, driven by increasing awareness, technological advancements, and an aging population.
New opportunities lie in:
- Develop digital therapeutics targeting delirium management.
- Invest in AI-driven diagnostic tools for early detection.
- Expand telehealth services for remote delirium monitoring.
By 2035, the Delirium Market is expected to achieve substantial growth, reflecting enhanced treatment options and increased market engagement.
Market Segmentation
Delirium Type Outlook
- Hyperactive
- Hypoactive
- Mixed
Delirium End User Outlook
- Hospitals
- Speciality Care
- Research Centers
Delirium Regional Outlook
North America
- US
- Canada
Delirium Diagnosis and treatment Outlook
Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
Report Scope
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.320 Billion |
| Market Size 2024 | USD 0.338 Billion |
| Market Size 2032 | USD 0.512 Billion |
| Compound Annual Growth Rate (CAGR) | 5.30% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019 to 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnosis and treatment, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland) |
| Key Market Opportunities | · Diagnostic Tools and Technologies· Educational and Training Programs |
| Key Market Dynamics | · Growing aging population· Improved identification and diagnosis· Technological advancements |
Market Highlights
Author
Latest Comments
John Doe
This is a great article! Really helped me understand the topic better.
Posted on July 23, 2025, 10:15
AM
Jane Smith
Thanks for sharing this. I’ve bookmarked it for later reference.
Posted on July 22, 2025, 7:45
PM
FAQs
How much is the Delirium market?
The Delirium Market is anticipated to reach 0.512 billion at a CAGR of 5.84% during the forecast period of 2023-2032.
How big is the US Delirium market?
The US is expected to hold a 70-80% share of the North American market for the Delirium market during the forecast period of 2023-2032.
What is the growth rate of the Delirium market?
The Delirium market is expected to grow at a 5.30% CAGR during the forecast period from 2024 to 2032.
Which region held the largest market share in the Delirium market?
The North American region market held the largest market share in the Delirium market.
Who are the key players in the Delirium market?
The key players include Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland).
Which type of Diagnosis and treatment led the Delirium market?
The diagnosis segment was estimated to lead the Delirium market.
Which end user had the largest market share in the Delirium market?
The Hospitals segment is attributed to having the largest market share based on end user.
-
' MESSAGES FROM THE MANAGEMENT: WHY MRFR? MRFR OFFERINGS SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
-
The Top Performing Segments
- Key Trends Summarized
- Pricing Outlook
- Strategic Insights
- Who are the Key Players in the Market? SECTION II: SCOPING
-
METHODOLOGY AND MARKET STRUCTURE
- Definition
- Report Segmentation & Scope
- Regional & Country Level Coverage
- Why you need this report?
- Research Process
- Secondary Research
-
Data Mining & Condensation
- Sources (Associations, Organizations, Magazines, Paid Databases)
-
Primary Research
- Sample Size (Demand-Supply
-
Company TYPE, Designations, Region)
- Sources
- Factorial Analysis & Approach Setting
- Estimation & Forecast Models
- Pricing Baskets
-
Analyst Hours & Team SECTION III: QUALITATIVE ANALYSIS
- Introduction
-
Growth Parameters Mapped - Drivers
- Growing aging population
- Improved identification and diagnosis
-
increasing demand for technologically advanced treatment
-
What are the challenges faced by Industry Participants?
- High cost of treatment
- Threat to data
-
What are the challenges faced by Industry Participants?
-
security &strict regulatory Compliance
-
Opportunities
- Collaboration with pharmaceutical companies and academic institutions
- Opportunity
- Opportunity
-
Value chain Analysis
- R&D and Designing
- Manufacturing
- Distribution & Sales
- Post Sales Services
- Porter’s Five Forces Model
-
Opportunities
-
Bargaining Power of Suppliers
-
Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
-
COVID-19 Impact Analysis
- Impact on R&D
- Impact on Pricing
- Impact on Regions
-
Bargaining Power of Buyers
-
SECTION IV: QUANTITATIVE ANALYSIS
- Introduction
-
Hyperactive
- Global Delirium
-
Market: Market Estimates & Forecast, By Hyperactive, 2019-2032
-
Hypoactive
- Global Delirium Market:
-
Hypoactive
-
Market Estimates & Forecast, By Hypoactive, 2019-2032
-
Mixed
- Global Delirium Market: Market Estimates
-
Mixed
-
Forecast, By Mixed, 2019-2032
- Introduction
-
Diagnosis
- Global Delirium
-
Market: Market Estimates & Forecast, By Diagnosis, 2019-2032
-
Laboratory Tests
- Physical Examination
- Imaging test
-
Treatment
- Global Delirium
-
Laboratory Tests
-
Market: Market Estimates & Forecast, By Treatment, 2019-2032
-
Antipsychotics
- Supportive care
-
Antipsychotics
-
BY END USER (USD MILLION)
- Introduction
-
Hospitals
- Global Delirium Market: Market Estimates & Forecast, By Hospitals, 2019-2032
- Speciality Care
-
Global Delirium Market: Market Estimates & Forecast, By Speciality Care, 2019-2032
-
Research Centers
- Global Delirium
-
Research Centers
-
Market: Market Estimates & Forecast, By Research Centers, 2019-2032
-
BY REGION (USD MILLION)
- Introduction
-
North America
- North America Delirium Market: Market Estimates & Forecast, By Country, 2019-2032
-
North America Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
- North America
-
Delirium Market: Market Estimates & Forecast, By Diagnosis and treatment, 2019-2032
- North America
-
Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
US
- US Delirium Market: Market
-
US
-
Estimates & Forecast, By Type, 2019-2032
- US Delirium Market: Market Estimates
-
Forecast, By Diagnosis and treatment, 2019-2032
- US Delirium Market: Market Estimates
-
Forecast, By End User, 2019-2032
-
Canada
- Canada Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
-
Canada
-
Canada Delirium Market: Market Estimates & Forecast, By Diagnosis and treatment
-
Canada Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
Mexico
- Mexico Delirium
-
Mexico
-
Market: Market Estimates & Forecast, By Type, 2019-2032
- Mexico Delirium Market: Market Estimates
-
& Forecast, By Diagnosis and treatment, 2019-2032
- Mexico Delirium Market: Market Estimates
-
& Forecast, By End User, 2019-2032
-
Europe
- Europe Delirium Market: Market Estimates
-
Europe
-
Forecast, By Country, 2019-2032
- Europe Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
-
Europe Delirium Market: Market Estimates & Forecast, By Diagnosis and treatment
-
Europe Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
Germany
- Germany Delirium
-
Germany
-
Market: Market Estimates & Forecast, By Type, 2019-2032
- Germany Delirium Market: Market Estimates
-
& Forecast, By Diagnosis and treatment, 2019-2032
- Germany Delirium Market: Market Estimates
-
& Forecast, By End User, 2019-2032
-
France
- France Delirium Market: Market Estimates
-
France
-
Forecast, By Type, 2019-2032
- France Delirium Market: Market Estimates & Forecast, By
-
Diagnosis and treatment, 2019-2032
- France Delirium Market: Market Estimates
-
Forecast, By End User, 2019-2032
- UK
-
UK Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
- UK Delirium
-
Market: Market Estimates & Forecast, By Diagnosis and treatment, 2019-2032
- UK Delirium
-
Market: Market Estimates & Forecast, By End User, 2019-2032
-
Spain
- Spain Delirium Market:
-
Spain
-
Market Estimates & Forecast, By Type, 2019-2032
- Spain Delirium Market: Market Estimates
-
& Forecast, By Diagnosis and treatment, 2019-2032
- Spain Delirium Market: Market Estimates
-
& Forecast, By End User, 2019-2032
-
Italy
- Italy Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
-
Italy
-
Italy Delirium Market: Market Estimates & Forecast, By Diagnosis and treatment
-
Italy Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
Rest of Europe
- Rest of Europe
-
Rest of Europe
-
Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
- Rest of Europe Delirium
-
Market: Market Estimates & Forecast, By Diagnosis and treatment, 2019-2032
- Rest of Europe
-
Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
Asia-Pacific
- Asia Pacific Delirium
-
Asia-Pacific
-
Market: Market Estimates & Forecast, By Country, 2019-2032
- Asia Pacific Delirium
-
Market: Market Estimates & Forecast, By Type, 2019-2032
- Asia Pacific Delirium Market: Market Estimates
-
& Forecast, By Diagnosis and treatment, 2019-2032
- Asia Pacific Delirium Market: Market Estimates
-
& Forecast, By End User, 2019-2032
-
China
- China Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
-
China
-
China Delirium Market: Market Estimates & Forecast, By Diagnosis and treatment
-
China Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
India
- India Delirium
-
India
-
Market: Market Estimates & Forecast, By Type, 2019-2032
- India Delirium Market: Market Estimates
-
& Forecast, By Diagnosis and treatment, 2019-2032
- India Delirium Market: Market Estimates
-
& Forecast, By End User, 2019-2032
-
Japan
- Japan Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
-
Japan
-
Japan Delirium Market: Market Estimates & Forecast, By Diagnosis and treatment
-
Japan Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
South Korea
- South Korea
-
South Korea
-
Delirium Market: Market Estimates & Forecast, By Type, 2019-2032
- South Korea Delirium
-
Market: Market Estimates & Forecast, By Diagnosis and treatment, 2019-2032
- South Korea
-
Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
Australia
- Australia Delirium
-
Australia
-
Market: Market Estimates & Forecast, By Type, 2019-2032
- Australia Delirium Market: Market Estimates
-
& Forecast, By Diagnosis and treatment, 2019-2032
- Australia Delirium Market: Market Estimates
-
& Forecast, By End User, 2019-2032
-
Rest of Asia-Pacific
- Rest of Asia-Pacific Delirium Market: Market
-
Rest of Asia-Pacific
-
Estimates & Forecast, By Type, 2019-2032
- Rest of Asia-Pacific Delirium Market: Market
-
Estimates & Forecast, By Diagnosis and treatment, 2019-2032
- Rest of Asia-Pacific
-
Delirium Market: Market Estimates & Forecast, By End User, 2019-2032
-
Rest of the world
- Middle East & Africa
-
Rest of the world
-
Middle East and Africa Delirium Market: Market Estimates & Forecast, By Type
-
Middle East and Africa Delirium Market: Market Estimates & Forecast, By Diagnosis and treatment, 2019-2032
- Middle East and Africa Delirium Market: Market Estimates
-
Forecast, By End User, 2019-2032
-
Latin America
- Latin America and Africa Delirium Market: Market Estimates
-
Latin America
-
& Forecast, By Type, 2019-2032
- Latin America Delirium Market: Market Estimates
-
& Forecast, By Diagnosis and treatment, 2019-2032
- Latin America Delirium Market: Market Estimates
-
& Forecast, By End User, 2019-2032
-
SECTION V: COMPETITIVE ANALYSIS
- Introduction
- Competition Dashboard
- Company Market Share Analysis, 2022-23 (%)
- Who are the market disruptors & innovators?
- What strategies are being adopted by market leaders?
- Competitive Benchmarking
- The Leading Player
-
in terms of Number of Developments in the Global Delirium Market
- List of Key Players, By Region
-
Public Players Stock Summary
- Comparative Analysis: Key Players Financial
- Key Developments & Growth Strategies
-
New Type Launch/Service Deployment
-
Merger & Acquisition
- Joint Ventures
-
Otsuka Pharmaceutical Co., Ltd
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Mylan N.V
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Teva Pharmaceutical Industries Ltd
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Zydus Group
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Glenmark Pharmaceuticals Ltd
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Pfizer
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Mylan N.V
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Teva Pharmaceutical Industries Ltd
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Glenmark Pharmaceuticals Ltd
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
-
Novartis AG
- Company Overview
- Financial Overview
- Product Offered
- Key Developments
- SWOT Analysis
- Key Strategies
- What is the short-term
-
Merger & Acquisition
-
vs long-term outlook for Delirium Market?
- Who are the players to look out for?
- What will the product
-
mix look in coming years?
- Citations & Media
- Our Regional Representatives
- Related Reports
- Our Domain Coverage NOTE:
-
This table of content
-
is tentative and subject to change as the research progresses.
-
In section 11, only the top
-
companies will be profiled. Each company will be profiled based on the Market Overview
-
Financials, Type Portfolio, Business Strategies, and Recent Developments parameters.
-
In section 11, SWOT
-
analysis will be provided for top
-
players
-
Please note: The financial details of the company
-
cannot be provided if the information is not available in the public domain and
-
or from reliable sources. LIST OF TABLES
-
MARKET FOR HYPERACTIVE MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
Delirium Market Segmentation
Delirium Drug Outlook (USD Billion, 2018-2032)
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Delirium Distribution Channel Outlook (USD Billion, 2018-2032)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Delirium Type Outlook (USD Billion, 2018-2032)
- Hyperactive
- Hypoactive
- Mixed
Delirium Diagnosis Outlook (USD Billion, 2018-2032)
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Delirium End-User Outlook (USD Billion, 2018-2032)
- Hospitals
- Research Centers
- Specialty Centers
Delirium Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
North America Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
North America Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
North America Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
North America Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
US Outlook (USD Billion, 2018-2032)
US Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
US Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
US Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
US Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
US Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
CANADA Outlook (USD Billion, 2018-2032)
CANADA Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
CANADA Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
CANADA Delirium by Type
- HYPERACTIVE
- Hypoactive
- Mixed
CANADA Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
CANADA Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Europe Outlook (USD Billion, 2018-2032)
Europe Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Europe Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Europe Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Europe Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Europe Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Germany Outlook (USD Billion, 2018-2032)
Germany Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Germany Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Germany Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Germany Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Germany Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
France Outlook (USD Billion, 2018-2032)
France Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
France Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
France Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
France Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
France Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
UK Outlook (USD Billion, 2018-2032)
UK Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
UK Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
UK Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
UK Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
UK Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
ITALY Outlook (USD Billion, 2018-2032)
ITALY Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
ITALY Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
ITALY Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
ITALY Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
ITALY Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
SPAIN Outlook (USD Billion, 2018-2032)
Spain Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Spain Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Spain Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Spain Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Spain Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
REST OF EUROPE Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
REST OF EUROPE Delirium by Type
- HYPERACTIVE
- Hypoactive
- Mixed
REST OF EUROPE Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
REST OF EUROPE Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Asia-Pacific Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Asia-Pacific Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Asia-Pacific Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Asia-Pacific Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
China Outlook (USD Billion, 2018-2032)
China Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
China Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
China Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
China Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
China Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Japan Outlook (USD Billion, 2018-2032)
Japan Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Japan Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Japan Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Japan Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Japan Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
India Outlook (USD Billion, 2018-2032)
India Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
India Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
India Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
India Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
India Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Australia Outlook (USD Billion, 2018-2032)
Australia Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Australia Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Australia Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Australia Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Australia Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Rest of Asia-Pacific Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Rest of Asia-Pacific Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Rest of Asia-Pacific Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Rest of Asia-Pacific Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Rest of the World Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Rest of the World Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Rest of the World Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Rest of the World Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Middle East Outlook (USD Billion, 2018-2032)
Middle East Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Middle East Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Middle East Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Middle East Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Middle East Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Africa Outlook (USD Billion, 2018-2032)
Africa Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Africa Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Africa Delirium by Type
- Hyperactive
- Hypoactive
- Mixed
Africa Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Africa Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Latin America Outlook (USD Billion, 2018-2032)
Latin America Delirium by Drug
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
Latin America Delirium by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Latin America Delirium by Type
- HYPERACTIVE
- Hypoactive
- Mixed
Latin America Delirium by Diagnosis
- Laboratory Tests
- Physical Examination
- Imaging test
- Blood test
- Urine test
Latin America Delirium by End-User
- Hospitals
- Research Centers
- Specialty Centers
Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment